Mavenclad

Active Ingredient(s): Cladribine
FDA Approved: * March 29, 2019
Pharm Company: * EMD SERONO INC
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Mavenclad Overview

Cladribine, sold under the brand name Leustatin and Mavenclad among others, is a medication used to treat hairy cell leukemia (HCL, leukemic reticuloendotheliosis), B-cell chronic lymphocytic leukemia and Relapsing-remitting Multiple Sclerosis (RRMS).[4][5] Its chemical name is 2-chloro-2'-deoxyadenosine (2CdA). As a purine analog, it is a synthetic chemotherapy agent that targets lymphocytes and selectively suppresses the immune system. Chemically, it mimics...

Read more Mavenclad Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Cladribine

Recent Mavenclad Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

NDC Database Records for Mavenclad: (1 result)

Sorted by National Drug Code

• 44087-4000 Mavenclad 10 mg Oral Tablet by Emd Serono, Inc.

Other drugs which contain Cladribine or a similar ingredient: (2 results)

• CLADRIBINE
• LEUSTATIN Cladribine